Introduction
============

Poststroke depression (PSD) is associated with higher risk of mortality, disability, and poor quality of life ([@B36]). About one in three stroke survivors present with PSD at any time after stroke ([@B36]). Understanding the underlying pathophysiology of PSD may facilitate developing better management strategies. Findings concerning the relationship between stroke locations and PSD have been inconsistent ([@B8]; [@B40]), which challenges the hypothesis that PSD is caused by a single lesion in the brain due to stroke ([@B32]).

Cerebral small vessel disease (SVD) is a composite term for a variety of chronic cerebral microvascular lesions resulting from aging, vascular risk factors or unknown etiologies ([@B39]). SVD is common in aging and stroke populations ([@B39]). The most characteristic markers of SVD on magnetic resonance imaging (MRI) are WMH, lacune, cerebral microbleeds, and enlarged perivascular spaces ([@B39]). A "SVD score" that includes the above four MRI markers was recently proposed to quantify the global damage to the small vessels of the brain caused by SVD ([@B31]). The SVD burden is associated with cognitive decline in hypertension ([@B37]), poststroke disability ([@B1]), recurrence of stroke ([@B18]), poor quality of life of stroke survivors ([@B20]), and depression after lacunar stroke ([@B46]).

Individual SVD markers have been shown to be associated with PSD ([@B27]; [@B34]). Only one study has reported an association between SVD burden and poststroke depressive symptoms (PDS) 3 months after lacunar stroke ([@B46]). However, the impact of SVD burden on the long-term prevalence of PSD has never been investigated. Similarly, the role of SVD burden in the development of PSD in a cohort comprising all subtypes of acute ischemic stroke is unclear. Hence, this study examined the association between SVD burden and poststroke depressive symptoms (PDS) during the first 15 months following an acute ischemic stroke.

Materials and Methods {#s1}
=====================

Study Population
----------------

The recruitment of the study sample is depicted in **Figure [1](#F1){ref-type="fig"}** where T0--T3 refer to assessment points at baseline, 3, 9, and 15 months after the index stroke, respectively. Patients with first-ever or recurrent acute ischemic stroke were consecutively screened following their admission to the Stroke Unit, Prince of Wales Hospital, Hong Kong, between January 2010 and October 2015. Due to the limited access to MRI, only 2,048 (32.1%) of all admitted stroke patients underwent an MRI examination within 1 week of the onset of stroke. A further 1,339 (62.0%) were excluded because they (1) refused to participate or were lost to follow-up; (2) had a history of psychiatric or neurologic disorders; (3) had severe comorbid medical conditions, such as multi-functional organs failure, cancer or severe systemic infection; (4) had severe aphasia, auditory or visual impairments; (5) deceased before the 15-month assessment; (6) had a recurrent stroke during the 15-month follow-up; and (7) were not of Chinese ethnicity.

![Flow chart of the study.](fnagi-10-00046-g001){#F1}

The study protocol was approved by the Joint Chinese University of Hong Kong New Territories East Cluster Clinical Research Ethics Committee. All participants gave written informed consent.

Demographic and Clinical Data
-----------------------------

Within 1 week of the index admission (T0), demographic (age, sex, and year of education) and clinical data on vascular risk factors (smoking, history of hypertension, diabetes mellitus, hyperlipidaemia, stroke, atrial fibrillation, and ischemic heart disease) were collected. Baseline stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS) ([@B6]) by a nurse from the Stroke Unit. Physical and cognitive functions and level of social support were assessed by a research assistant with the Barthel Index (BI) ([@B3]), the Mini-Mental State Examination (MMSE) ([@B11]), and the Lubben Social Network Scale (LSNS) ([@B23]), respectively at T1, T2, and T3.

Study Outcomes
--------------

The primary study outcome was PDS at either T1, T2, or T3. All patients were screened for PDS with the 15-item Geriatric Depression Scale (GDS) by a psychiatrist (W-KT). Clinically significant PDS suspect for an ongoing depressive illness was defined by a score 7 or above on the GDS ([@B33]). The 15-item GDS has good sensitivity (89%) and specificity (73%) in screening for PDS in a Hong Kong stroke population ([@B33]).

Neuroimaging
------------

All patients were scanned on a 1.5-T MRI system (Sonata; Siemens Medical Systems Inc., Germany) with diffusion weighted, gradient echo, T1- and T2-weighted and fluid attenuated inversion recovery sequences. The MRI parameters were described in detail elsewhere ([@B20]). A qualified neurologist (YL) blind to all demographic and clinical information reviewed the MRI data on SVD markers, while another qualified neurologist (Y-KC) conducted the measurement on infarcts. The numbers and volumes of acute and old infarcts were recorded. The details of the scoring method on 'SVD burden' were described earlier ([@B20]). Briefly, based on a validated scale ([@B31]), the presence of either lacune, cerebral microbleeds, extensive WMH, or moderate to severe enlarged perivascular spaces was awarded one point. Summing the above four subscores produced a total SVD score ranging from 0 to 4. The inter-rater reliability of the MRI characteristics was determined by comparing 30 randomly selected MRI scans rated separately by YL and Y-KC. The inter-rater kappa coefficient values were 0.76 for lacune; 0.63 for periventricular WMH, 0.62 for deep WMH; 0.78 for cerebral microbleeds, 0.80 for enlarged perivascular spaces; and 0.66 for both acute and old infarcts.

Statistical Analysis
--------------------

SPSS Statistics, Version 20.0 software (IBM) was used for the statistical analysis. Data are presented as mean ± standard deviation (SD), median (interquartile range, IQR), or proportions, as appropriate. The normality of the data was tested with the Shapiro--Wilk test. To ascertain the associations between SVD burden and PDS during the 15-month follow-up, generalized estimating equation (GEE) models were constructed by including patients attending both the first (T1) and the last (T3) follow-ups (*n* = 563). The summed and individual SVD scores were entered the multivariate GEE models, adjusting for demographic, clinical and imaging characteristics. The level of significance was set at 0.05 (two-tailed).

Results
=======

Characteristics of the Study Sample
-----------------------------------

A total of 563 patients were enrolled at both T1 and T3; 146 (20.5%) patients defaulted at follow-up. **Table [1](#T1){ref-type="table"}** lists the characteristics of the study sample and the patients who defaulted. The stroke severity of the study sample was lower than that of patients excluded from the study \[NIHSS scores of 3 (1--5) vs. 4 (1--11); *p* \< 0.001; data not shown\].

###### 

Comparison of demographic, clinical and MRI characteristics between the study sample and the patients withdrawn from the study.

                                                 Included      Withdrawn
  ---------------------------------------------- ------------- -------------
  **Demographics**                                             
  Age, years, mean ±*SD*                         67.0 ± 10.2   67.1 ± 11.4
  Female sex, *n* (%)                            230 (40.9)    52 (35.6)
  Education, years, mean ±*SD*                   6.7 ± 4.2     6.7 ± 5.1
  **Vascular risk factors, *n* (%)**                           
  Current or previous smoker                     214 (38.0)    63 (42.9)
  Hypertension                                   364 (64.7)    98 (67.6)
  Hyperlipidemia                                 240 (42.6)    52 (35.9)
  Diabetes mellitus                              159 (28.2)    44 (30.3)
  Previous stroke                                56 (9.9)      19 (13.1)
  Ischemic heart disease                         26 (4.6)      8 (5.5)
  Atrial fibrillation                            24 (4.3)      16 (11.0)
  **Stroke characteristics**                                   
  NIHSS on admission, median (IQR)               3 (1--5)      3 (1--5)
  Volume of acute infarcts, ml, mean ± SD        3.2 ± 9.6     3.5 ± 9.1
  Number of acute infarcts, mean ±*SD*           1.3 ± 2.2     1.1 ± 1.1
  Old infarcts, *n* (%)                          114 (20.2)    58 (39.7)
  **Location of acute infarcts, *n* (%)**                      
  Cortical                                       96 (17.1)     31 (21.2)
  Subcortical white matter                       173 (30.7)    36 (24.7)
  Deep                                           127 (22.6)    31 (21.2)
  Infratentorial                                 80 (14.2)     30 (20.5)
  **SVD individual markers**                                   
  Lacune, *n* (%)                                113 (20.1)    28 (19.2)
  Cerebral microbleeds, *n* (%)                  76 (13.5)     29 (19.9)
  Perivascular WMH, median (IQR)                 1 (1--2)      1 (1--2)
  Deep WMH, median (IQR)                         1 (1--2)      1 (1--2)
  Enlarged perivascular spaces, median (IQR)     1 (1--2)      1 (0--2)
  **SVD burden**                                               
  SVD score, median (IQR)                        1 (0--2)      1 (0--2)
  SVD score = 0, *n* (%)                         248 (44.0)    57 (39.0)
  SVD score = 1, *n* (%)                         134 (23.8)    30 (20.5)
  SVD score = 2, *n* (%)                         103 (18.3)    36 (24.7)
  SVD score = 3, *n* (%)                         54 (9.6)      15 (10.3)
  SVD score = 4, *n* (%)                         24 (4.3)      8 (5.5)
  **Clinical assessments**                                     
  Social support: LSNS, mean ±*SD*               28.3 ± 8.4    28.5 ± 8.7
  **PDS, *n* (%)**                                             
  T1                                             103 (18.3)    20 (13.7)
  T2                                             53 (11.6)     --
  T3                                             69 (12.3)     --
  **Severity of PDS: GDS, median (IQR)**                       
  T1                                             2 (1--5)      2 (1--4)
  T2                                             2 (1--4)      --
  T3                                             2 (1--4)      --
  **Functional independence: BI, mean ± *SD***                 
  T1                                             19.1 ± 2.1    19.1 ± 1.9
  T2                                             19.0 ± 2.3    --
  T3                                             19.1 ± 2.1    --
  **Cognitive function: MMSE, mean ± *SD***                    
  T1                                             26.9 ± 3.1    26.5 ± 3.4
  T2                                             27.1 ± 3.2    --
  T3                                             26.7 ± 3.7    --

BI, Barthel Index; GDS, Geriatric Depression Scale; IQR, interquartile range; LSNS, Lubben Social Network Scale; MMSE, Mini--Mental State Examination; MRI, Magnetic Resonance Imaging; NIHSS, National Institutes of Health Stroke Scale; PDS, poststroke depressive symptoms; SD, standard deviation; SVD, small vessel disease; WMH, white matter hyperintensities

.

The demographic, clinical and imaging characteristics are shown in **Table [1](#T1){ref-type="table"}**. The study sample had a mean age of 67.0 ± 10.2 years; 40.9% were female. The stroke severity was mainly mild to moderate with a median NIHSS score of 3 (IQR, 1--5); 44.0% of the sample had no marked SVD (SVD score = 0) while the median SVD score was 1 (IQR, 0--2). Levels of social support (LSNS: 28.3 ± 8.4), functional independence (BI: 19.1 ± 2.1) and cognitive functions (MMSE: 26.9 ± 3.1) were relatively high. The level of PDS was low with a median GDS score of 2 across the three assessments. The frequency of clinically meaningful PDS at T1, T2, and T3 was 18.3% (103), 11.6% (53), and 12.4% (69), respectively.

Association Between SVD and PDS
-------------------------------

The results of the multivariate GEE model are shown in **Table [2](#T2){ref-type="table"}**. The combined SVD score (OR: 1.30, 95% CI: 1.07--1.58; *p* = 0.010) was a significant predictor of PDS over the 15-month follow-up. None of the four individual SVD markers (lacune: *p* = 0.720; cerebral microbleeds: *p* = 0.066; WMH: *p* = 0.430; enlarged perivascular spaces: *p* = 0.369) was significantly associated with PDS in the multivariate GEE models (data not shown).

###### 

Multivariate GEE model on the association between PDS and baseline characteristics.

  Significant predictors^a^        OR (95%CI)              *p*
  -------------------------------- ----------------------- -----------
  **Time points of assessments**                           
  T1                               Reference               
  T2                               0.60 (0.42--0.85)       0.004
  T3                               0.61 (0.45--0.82)       0.001
  **Sex**                                                  
  Male                             Reference               
  Female                           1.80 (1.02--3.17)       0.042
  **Smoking**                                              
  Non-smoker                       Reference               
  Current or previous smoker       1.75 (1.06--2.90)       0.029
  Social support (LSNS)            0.96 (0.93--0.98)       \<0.001
  **SVD burden (SVD score)**       **1.30 (1.07--1.58)**   **0.010**
  Number of acute infarcts         1.11 (1.02--1.20)       0.014
  Functional independence (BI)     0.87 (0.81--0.92)       \<0.001

BI, Barthel Index; CI, confidence interval; GEE, generalized estimating equation; LSNS, Lubben Social Network Scale; OR, odds ratio; PDS, poststroke depressive symptoms; SVD, small vessel disease

.

a

All the predictors listed here were adjusted for assessment time points, age, sex, social support, vascular risk factors, stroke severity, location, number and volume of acute infarcts, old infarcts, SVD burden, cognitive function, and functional independence

.

Other Predictors of PDS
-----------------------

Other significant predictors of PDS were female sex (OR: 1.80, 95% CI: 1.02--3.17, *p* = 0.042); smoking (OR: 1.75, 95% CI: 1.06--2.90, *p* = 0.029); number of acute infarcts (OR:1.11, 95% CI: 1.02--1.20, *p* = 0.014); time of assessment at T2 (OR: 0.60, 95% CI: 0.42--0.85, *p* = 0.004) and T3 (OR: 0.61, 95% CI: 0.45--0.82, *p* = 0.001) compared with T1; higher level of social support (OR: 0.96, 95% CI: 0.93--0.98, *p* \< 0.001); and functional independence (OR: 0.87, 95% CI: 0.81--0.92, *p* \< 0.001) (**Table [2](#T2){ref-type="table"}**).

Discussion
==========

The main finding of this study is that SVD burden is associated with clinically meaningful PDS over a 15-month follow-up period in patients with mild to moderate acute ischemic stroke. To the best of our knowledge, this was the first longitudinal study that examined the relationship between SVD burden and PDS after stroke.

It is of note that the SVD burden rather than any single SVD marker was associated with PDS. Higher SVD burden is associated with risk of depression 3 months after lacunar stroke ([@B46]). The current study extended this finding by conducting a 15-month follow-up to ascertain the long-term impact of the baseline SVD burden on PDS. All subtypes of ischemic stroke were included because lacunar strokes only account for 25% of ischemic strokes ([@B16]). Total SVD burden has been suggested to be a better predictor of stroke outcomes, including mortality ([@B30]), disability ([@B1]), stroke recurrence ([@B18]), and poor quality of life ([@B20]), than a single SVD marker. The findings of this study lend further support to the hypothesis that chronic vascular burden in the brain is a critical neuroanatomical factor in depression in older adults ([@B28]).

The underlying mechanisms linking SVD burden to poststroke PDS are poorly understood. Functional disability and cognitive impairment may be mediating factors as they confer the highest risk for PSD ([@B36]). SVD lesions reduce the brain's 'reserve' against vascular insults and its plasticity ([@B24]). Stroke patients with more severe SVD are prone to have larger infarct volume ([@B14]), impaired reperfusion ([@B2]), and recurrent stroke ([@B18]). Consequently, disability and cognitive decline were more likely to occur among stroke survivors with severe SVD burden ([@B15]; [@B1]). However, after adjustment for acute infarcts, stroke severity, functional independence, and cognition in this study, SVD burden remained a significant predictor of PDS. This suggests that SVD burden might contribute to the development of PDS via other paths. From a network viewpoint, the integrity of both the structural and functional global network is the key prerequisite for recovery from stroke ([@B21]) and emotional modulation ([@B13]). SVD leads to the disruption of white matter integrity of frontal-subcortical circuit which is thought to be critical in the pathogenesis of depression ([@B38]). Reduced global structural network efficiency arising from SVD has recently been shown to be associated with depression ([@B45]).

The pathomechanism of PSD is not yet clarified. In addition to the 'vascular depression hypothesis' as mentioned above, evidence is emerging to support the notion that inflammation could also play a role in the development of PSD ([@B25]; [@B4]). Higher level of inflammatory markers was recently found to be predictor of PSD ([@B10]) and anti-inflammatory treatment has shown promising results in reducing risk of PSD ([@B42]). Furthermore, SVD burden was found to be associated with systemic lupus erythematosus, a systemic inflammatory disease ([@B41]). Enlarged perivascular spaces, one of the SVD markers, was proposed as an MRI marker of neuroinflammatory activity and was associated with lesions in multiple sclerosis ([@B44]). The above findings suggest that SVD burden could be an epiphenomenon of the accumulating inflammatory processes.

Medical comorbidities are the 'silent contributors' to stroke outcomes ([@B26]). Intracranial atherosclerosis and diabetes were recently reported to be risk factors of early-onset and late-onset PSD, respectively ([@B9]; [@B47]); smoking, as also demonstrated in this study, was associated with PDS. It is suggested that these comorbidities join SVD to promote a chronic proinflammatory state and fuel acute neuroinflammation in the event of acute stroke ([@B12]; [@B26]). The aggravated neuroinflammation, in turn, causes the downstream neurodegeneration, neuronal apoptosis, and impaired neuroplasticity ([@B19]), disrupt the depression-related neurocircuits ([@B22]), and eventually result in depressive symptoms or other unfavorable outcomes ([@B12]). Taken together, PSD or PDS could be viewed as a consequence of a complex interplay between stroke, pre-stroke comorbidities, and neuroinflammation ([@B26]).

Other predictors of PDS in the present study were female sex, lower levels of functional independence and social support, smoking, the time of the assessment, and the number of acute infarcts. Female sex, lower level of functional independence and social support have been consistently reported as risk factors of PSD ([@B36]). Smoking also increases the risk of PSD in minor stroke ([@B29]).

In this study, the risk of PDS was decreasing during the 15-month follow-up. A one-year follow-up study reported that the prevalence of depression decreased from 18.8% at 1 month to 14.6% ([@B5]). A similar decline in PSD from 6.7% at 3 months to 5.1% at 1 year has also been reported ([@B17]). The number of acute infarcts predicted PDS in the present study, which is consistent with the finding that more severe lacunar infarcts are associated with PSD ([@B27]; [@B43]).

The major strengths of this study are its prospective design, large sample size and its relatively long 15-month follow-up after the index stroke. The first major limitation is that this study mainly included mild to moderate stroke patients. This selection bias reduces the generalizability of the results, including the relationship of SVD burden and PDS in acute ischemic stroke. Second, the lack of comprehensive clinical assessment of depression limits the clinical implications of the study, although PDS also have detrimental effects on stroke outcomes ([@B36]). Nevertheless, the GDS is a reliable tool to detect PDS in this stroke population and has been shown to be useful for screening PDS in Hong Kong elderly stroke patients with good sensitivity and specificity ([@B33],[@B35]). A systemic review has also confirmed that the GDS could detect milder PDS in the elderly ([@B7]). The third limitation is the lack of etiological differentiation of ischemic stroke due to the limited clinical information. Hence, the study could not clarify the differential impact of SVD burden on PDS with respect to the subtypes of acute ischemic stroke. Fourth, about a quarter of eligible patients were lost to follow-up. To offset this limitation, GEE analysis was used to handle missing data. Fifth, this was an observational study without comprehensive investigation of the inflammatory markers or comorbidities. Moreover, we are aware that ideally the assessment of imaging data should be conducted by two raters despite of moderate to good interrater agreements, however, this study failed to provide confirming assessments by a second rater due to the limited manpower. Finally, the 15-month follow-up could not draw conclusions about the association between SVD burden and longer-term clinical course of PDS.

Conclusion
==========

SVD burden was associated with clinically significant PDS over a 15-month follow-up in patients with mild to moderate acute ischemic stroke. The findings lend further support to the hypothesis of vascular depression suggesting that accumulating microvascular lesions are critical for the development of depressive symptoms. Measurement of SVD burden might facilitate the early identification of patients at risk of PDS after mild to moderate acute ischemic stroke. Multimodal imaging studies from a network perspective would be useful to clarify the underlying mechanisms linking SVD to PDS. Investigations of the impact of SVD burden on the effectiveness of antidepressant treatment in PDS are also warranted.
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